COVID-19 threatens to exacerbate the national opioid crisis by reducing availability and access to harm reduction and health services delivered by syringe service programs (SSPs). Monitoring the impact of COVID- 19 on the availability and delivery of harm reduction and health services by SSPs in the U.S. over time is imperative for guiding local and national opioid policies. Failure to restore services will require additional responses to avoid adverse consequences, including HIV and hepatitis C outbreaks, whereas potentially beneficial responses, such as eliminating 1:1 syringe exchange requirements, should be disseminated widely. This supplement proposes collecting and analyzing longitudinal data on the impact of recovery from COVID-19 on SSPs. We will describe the changes in national SSP services in response to COVID-19 over one year via qualitative interviews and short surveys with SSPs every 6 months. Interviews will explore changes in harm reduction and health services offered; funding, adoption and sustainment of innovative services and service delivery; and barriers and facilitators for SSPs to delivering different services over a year. Descriptive data analysis will be conducted to determine if programs recover, maintain, or adapt services 6 and 12 months after the baseline survey. Qualitative data will be analyzed using content analysis. We will also conduct a longitudinal analysis to determine the associations between COVID-19 reported infections, COVID-19 response policies, and SSP services delivered. SSPs registered with the North American Syringe Exchange Network will be invited to participate in the longitudinal study that will collect monthly data on 1) number of syringes dispensed, 2) number of naloxone kits dispensed, 3) estimated number of participants served (directly and through secondary exchange), and 4) whether the SSP offered any on-site HIV or HCV testing in that month. COVID-19 reported infections and policies will be derived from publicly available data sources. We will conduct interrupted time series analysis to determine if changes in local COVID-19 stay-at-home policies are associated with changes in the monthly number of syringes and naloxone distributed and per client rates, taking into account reported local infection rates. Time-to-event analysis will be used to assess the impact of COVID-19 infection rates and policies on HIV and HCV testing. Results will be disseminated to national and local policy makers to support decision making for harm reduction and health services provided to people who inject drugs.

Public Health Relevance

COVID-19 threatens to exacerbate the national opioid crisis by reducing availability and access to harm reduction and health services delivered by syringe service programs (SSPs). This supplement proposes collecting and analyzing longitudinal data on the impact of COVID-19 response policies and epidemiology on the services provided by SSPs using quantitative and qualitative analysis methods. Results will be disseminated to national and local policy makers to support decision making for harm reduction and health services provided to people who inject drugs.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
3R01DA027379-08S1
Application #
10192052
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Duffy, Sarah Q
Project Start
2009-09-01
Project End
2022-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
8
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Other Health Professions
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Traynor, Sharleen M; Rosen-Metsch, Lisa; Feaster, Daniel J (2018) Missed Opportunities for HIV Testing Among STD Clinic Patients. J Community Health 43:1128-1136
Schackman, Bruce R; Gutkind, Sarah; Morgan, Jake R et al. (2018) Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. Drug Alcohol Depend 185:411-420
Behrends, Czarina N; Nugent, Ann V; Des Jarlais, Don C et al. (2018) Availability of HIV and HCV On-Site Testing and Treatment at Syringe Service Programs in the United States. J Acquir Immune Defic Syndr 79:e76-e78
Feaster, Daniel J; Parish, Carrigan L; Gooden, Lauren et al. (2016) Substance use and STI acquisition: Secondary analysis from the AWARE study. Drug Alcohol Depend 169:171-179
Perlman, David C; Jordan, Ashly E; Uuskula, Anneli et al. (2015) An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. Int J Drug Policy 26:1056-63
Schackman, Bruce R; Leff, Jared A; Barter, Devra M et al. (2015) Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction 110:129-43
Linas, Benjamin P; Barter, Devra M; Morgan, Jake R et al. (2015) The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 162:619-29
Linas, Benjamin P; Barter, Devra M; Leff, Jared A et al. (2014) The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS 28:365-76
Linas, Benjamin P; Barter, Devra M; Leff, Jared A et al. (2014) The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One 9:e97317
Pho, Mai T; Linas, Benjamin P (2014) Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy. Hepatology 60:12-4

Showing the most recent 10 out of 16 publications